open access

Vol 10, No 3 (2021)
Research paper
Published online: 2020-11-23
Get Citation

The anti-proliferative role of metformin in non-diabetic female patients with breast cancer: systematic review and meta-analysis of randomized control trials

Hanan A Al-Ghalib12, Afnan D Al-Otaibi12, Bader Al Tulaihi3, Shatha Al-Ghaleb4
DOI: 10.5603/DK.2020.0062
·
Clinical Diabetology 2021;10(3):252-260.
Affiliations
  1. King Abdulaziz Medical City, Riyadh, 00966 Riaydh, Saudi Arabia
  2. 1Department of Family Medicine and Primary Health Care, King Abdulaziz Medical City, Ministry of National Guard - Health Affairs. Family Medicine and Primary Health Care Residency Training Program
  3. Asst. Professor, COM, KSAU-HS Consultant, Family Medicine Ministry of National Guard-HA, Riaydh, 00966 Riaydh, Saudi Arabia
  4. Consultant, Department of Family Medicine and Primary Health Care, Prince Sultan Military Medical City, Riyadh, Saudi Arabia., riaydh, 00966 riaydh, Saudi Arabia

open access

Vol 10, No 3 (2021)
Original articles (submitted)
Published online: 2020-11-23

Abstract

Background. Usage of metformin in non-diabetic women
with breast cancer is neither a common approach
nor a conventional treatment modality. Metformin
and chemotherapy have a high phenotypic variation
in complete response rate among diabetic patients
with different types of cancer. Although the results
on salvage therapy were contradictory, we carried out
a meta-analysis to evaluate the effect of the addition
of metformin to conventional treatment on the prognosis
in non-diabetic women who have breast cancer.

Methods. A consummate literature search of Pub-
Med, EMBASE, grey literature, and web of science
was conducted until 7th of March 2020. A total of 11
randomized control trials were included in this metaanalysis
including references related to metformin,
breast cancer, and prognosis. The search was limited to
English language and human studies, including references
related to metformin, breast cancer, and prognosis.
We performed the meta-analysis using a random
and fixed-effects model, with hazard ratios and 95%
confidence intervals (95% CI) as effect measures.

Results. A total of 11 randomized control trials consisting
of 1681 breast cancer patients without diabetes
including 841 ones which received metformintreatement
versus 840 ones not treated with metformin.
The meta-analysis found that metformin has been
linked with anti-proliferative role (HR 0.63, 95% CI
0.59–0.71). Subgroup analysis showed an increased average
progression of free survival which demonstrates
that metformin improves overall survival by 65% after
correcting for hormone-receptor/gene expression (HR
0.35, 95% CI 0.15–0.84). Taking metformin as treatment
of breast cancer has been related to extended
survival rate.

Conclusion. This meta-analysis supports the potential
role of metformin in the management of cancer, as it
may increase progression free survival among nondiabetic
patients with breast cancer. More clinical trials
are needed for further exploration of metformin role,
and to determine whether improvements in cancer
care can be achieved with adding metformin to reduce
mortality or to improve overall survival in patients with
breast cancer.

Abstract

Background. Usage of metformin in non-diabetic women
with breast cancer is neither a common approach
nor a conventional treatment modality. Metformin
and chemotherapy have a high phenotypic variation
in complete response rate among diabetic patients
with different types of cancer. Although the results
on salvage therapy were contradictory, we carried out
a meta-analysis to evaluate the effect of the addition
of metformin to conventional treatment on the prognosis
in non-diabetic women who have breast cancer.

Methods. A consummate literature search of Pub-
Med, EMBASE, grey literature, and web of science
was conducted until 7th of March 2020. A total of 11
randomized control trials were included in this metaanalysis
including references related to metformin,
breast cancer, and prognosis. The search was limited to
English language and human studies, including references
related to metformin, breast cancer, and prognosis.
We performed the meta-analysis using a random
and fixed-effects model, with hazard ratios and 95%
confidence intervals (95% CI) as effect measures.

Results. A total of 11 randomized control trials consisting
of 1681 breast cancer patients without diabetes
including 841 ones which received metformintreatement
versus 840 ones not treated with metformin.
The meta-analysis found that metformin has been
linked with anti-proliferative role (HR 0.63, 95% CI
0.59–0.71). Subgroup analysis showed an increased average
progression of free survival which demonstrates
that metformin improves overall survival by 65% after
correcting for hormone-receptor/gene expression (HR
0.35, 95% CI 0.15–0.84). Taking metformin as treatment
of breast cancer has been related to extended
survival rate.

Conclusion. This meta-analysis supports the potential
role of metformin in the management of cancer, as it
may increase progression free survival among nondiabetic
patients with breast cancer. More clinical trials
are needed for further exploration of metformin role,
and to determine whether improvements in cancer
care can be achieved with adding metformin to reduce
mortality or to improve overall survival in patients with
breast cancer.

Get Citation

Keywords

apoptosis, metformin, non-diabetic, females, patients, breast cancer, systematic review, meta-analysis, randomized control trials

About this article
Title

The anti-proliferative role of metformin in non-diabetic female patients with breast cancer: systematic review and meta-analysis of randomized control trials

Journal

Clinical Diabetology

Issue

Vol 10, No 3 (2021)

Article type

Research paper

Pages

252-260

Published online

2020-11-23

DOI

10.5603/DK.2020.0062

Bibliographic record

Clinical Diabetology 2021;10(3):252-260.

Keywords

apoptosis
metformin
non-diabetic
females
patients
breast cancer
systematic review
meta-analysis
randomized control trials

Authors

Hanan A Al-Ghalib
Afnan D Al-Otaibi
Bader Al Tulaihi
Shatha Al-Ghaleb

References (25)
  1. Siegel RL, Fedewa SA, Miller KD, et al. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1): 5–29.
  2. Alimova IN, Liu B, Fan Z, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009; 8(6): 909–915.
  3. Goodwin PJ. Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions? J Clin Oncol. 2008; 26(6): 833–834.
  4. Hadad SM, Fleming S, Thompson AM. Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol. 2008; 67(1): 1–7.
  5. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009; 27(20): 3297–3302.
  6. Aljofan M, Riethmacher D. Anticancer activity of metformin: a systematic review of the literature. Future Sci OA. 2019; 5(8): FSO410.
  7. Lee JHa, Kim TIl, Jeon SM, et al. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer. 2012; 131(3): 752–759.
  8. Yin M, Zhou J, Gorak EJ, et al. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. Oncologist. 2013; 18(12): 1248–1255.
  9. Moher D, Shamseer L, Clarke M, et al. PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4(1): 345–351.
  10. von Elm E, Altman DG. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reportingobservational studies. Lancet. 2007; 370: 1453–1457.
  11. Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus:Asystematic reviewandmetaanalysis. JAMA. 2008; 300: 2754–2764.
  12. Begg C, Mazumdar M. Operating Characteristics of a Rank Correlation Test for Publication Bias. Biometrics. 1994; 50(4): 1088–1101.
  13. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109): 629–634.
  14. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56(2): 455–463.
  15. Bikas A, Jensen K, Patel A, et al. Glucose-deprivation increases thyroid cancer cells sensitivity to metformin. Endocr Relat Cancer. 2015; 22(6): 919–932.
  16. Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res. 2010; 16(6): 1695–1700.
  17. Jiralerspong S, Kim ES, Dong W, et al. Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol. 2013; 24(10): 2506–2514.
  18. Richardson LC, Pollack LA. Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol. 2005; 2(1): 48–53.
  19. Bayraktar S, Hernadez-Aya LF, Lei X, et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer. 2012; 118(5): 1202–1211.
  20. Zhang ZJ, Li S. The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014; 16(8): 707–710.
  21. Zhou PT, Li Bo, Liu FR, et al. Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis. Oncotarget. 2017; 8(15): 25242–25250.
  22. Bowker SL, Yasui Y, Veugelers P, et al. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia. 2010; 53(8): 1631–1637.
  23. Sadeghi N, Abbruzzese JL, Yeung SCJ, et al. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res. 2012; 18(10): 2905–2912.
  24. Terrin N, Schmid CH, Lau J, et al. Adjusting for publication bias in the presence of heterogeneity. Stat Med. 2003; 22(13): 2113–2126.
  25. Peters JL, Sutton AJ, Jones DR, et al. Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med. 2007; 26(25): 4544–4562.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl